Skip to content
Homepage
Author:
Zealand Pharma
Posted Date:
November 12, 2026
Zealand Pharma Announces Financial Results for the First Nine Months of 2026
Zealand Pharma
November 12, 2026
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
Zealand Pharma
November 9, 2026
Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits
Zealand Pharma
November 9, 2026
Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results
Zealand Pharma
November 5, 2026
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
Zealand Pharma
October 19, 2026
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma
October 13, 2026
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
Zealand Pharma
October 1, 2026
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Zealand Pharma
October 1, 2026
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Zealand Pharma
September 29, 2026
Zealand Pharma – Transactions related to share buy-back program (week 39, 2026)
Zealand Pharma
September 28, 2026
1
2
3
…
5
Next
